Navigation Links
Researchers identify mechanisms that allow embryonic stem cells to become any cell in the human body
Date:7/18/2012

New research at the Hebrew University of Jerusalem sheds light on pluripotencythe ability of embryonic stem cells to renew themselves indefinitely and to differentiate into all types of mature cells. Solving this problem, which is a major challenge in modern biology, could expedite the use of embryonic stem cells in cell therapy and regenerative medicine. If scientists can replicate the mechanisms that make pluripotency possible, they could create cells in the laboratory which could be implanted in humans to cure diseases characterized by cell death, such as Alzheimer's, Parkinson's, diabetes and other degenerative diseases.

To shed light on these processes, researchers in the lab of Dr. Eran Meshorer, in the Department of Genetics at the Hebrew University's Alexander Silberman Institute of Life Sciences, are combining molecular, microscopic and genomic approaches. Meshorer's team is focusing on epigenetic pathwayswhich cause biological changes without a corresponding change in the DNA sequencethat are specific to embryonic stem cells.

The molecular basis for epigenetic mechanisms is chromatin, which is comprised of a cell's DNA and structural and regulatory proteins. In groundbreaking research performed by Shai Melcer, a PhD student in the Meshorer lab, the mechanisms which support an "open" chromatin conformation in embryonic stem cells were examined. The researchers found that chromatin is less condensed in embryonic stem cells, allowing them the flexibility or "functional plasticity" to turn into any kind of cell.

A distinct pattern of chemical modifications of chromatin structural proteins (referred to as the acetylation and methylation of histones) enables a looser chromatin configuration in embryonic stem cells. During the early stages of differentiation, this pattern changes to facilitate chromatin compaction.

But even more interestingly, the authors found that a nuclear lamina protein, lamin A, is also a part of
'/>"/>

Contact: Dov Smith
dovs@savion.huji.ac.il
972-258-81641
The Hebrew University of Jerusalem
Source:Eurekalert  

Page: 1 2

Related biology news :

1. Caltech researchers find evidence of link between immune irregularities and autism
2. Stanford researchers calculate global health impacts of the Fukushima nuclear disaster
3. Johns Hopkins researchers link 2 biological risk factors for schizophrenia
4. U of S researchers discover cannabis pharma factory
5. Researchers develop new method for identifying lung nodules
6. UMMS researchers isolate gene mutations in patients with inherited amyotrophic lateral sclerosis
7. Cleveland Clinic researchers receive $5 million grant to discover novel pathways to heart disease
8. Researchers take hibiscus efforts to commercialization
9. UI researchers develop technique to help pollution forecasters see past clouds
10. UC Santa Barbara researchers play key role in UN Environmental Assessment
11. Researchers discover molecule in immune system that could help treat dangerous skin cancer
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Researchers identify mechanisms that allow embryonic stem cells to become any cell in the human body
(Date:9/17/2014)... (Sept. 17, 2014) A rare genetic disorder known as ... a recent joint investigation by researchers at San Diego ... In addition to suggesting better treatment options for people ... into the genetic underpinnings of autism., Jacobsen syndrome affects ... Institutes of Health. It occurs in a person when ...
(Date:9/17/2014)... Mar Medical Research Institute) and at the Universitat Politcnica ... eLife showing that RNA called non-coding (IncRNA) ... proteins, some of which could have important cell functions ... instructions found in an RNA molecule. However, only 2% ... the synthesis of proteins, meaning it is coding. Other ...
(Date:9/17/2014)... 17, 2014 Researchers at UTSouthwestern Medical Center have ... protein apolipoprotein E, called apoE3, helps repair the lining ... do not get the benefit of this repair, putting ... believe that we have identified one mechanism by which ... genetic variant, apoE4, is detrimental," said Dr. Philip ...
Breaking Biology News(10 mins):A link between Jacobsen syndrome and autism 2Parts of genome without a known function may play a key role in the birth of new proteins 2Protein variant may boost cardiovascular risk by hindering blood vessel repair 2
... and use of commercial fertilisers and animal waste is ... our aquatic environment. Yet global food and bioenergy supplies ... Agriculture and Ecology at LIFE Faculty of Life ... massive resources at the development of sustainable animal waste ...
... a popular species of game fish in Lake Erie are ... most comprehensive to date on mercury levels in Great Lakes ... a semi-monthly journal. Satyendra Bhavsar and colleagues note ... lakes in the world. The lakes are of significant economic ...
... 20, 2010) -- The Howard Hughes Medical Institute (HHMI) ... Rice University,s successful undergraduate global health program Beyond Traditional ... million HHMI grant in 2006, challenges students to come ... developing world. The program has captured the imagination of ...
Cached Biology News:Massive resources now directed at sustainable animal waste technology 2HHMI renews grant for Rice's global health program 2
(Date:9/17/2014)... FRANCISCO , Sept. 17, 2014 ... receiving accelerated partial breast irradiation (APBI) via interstitial ... those with positive lymph nodes could be suitable ... Radiation Oncology (ASTRO) guidelines place these patients in ... abstract at the 2014 ASTRO meeting, Beaumont Health ...
(Date:9/17/2014)... , Sept. 17, 2014 /PRNewswire/ - Oncothyreon Inc. ... intends to offer and sell shares of its Common ... but concurrent underwritten public offerings.  The Series A Convertible ... Oncothyreon Common Stock, provided that conversion will be prohibited ... would beneficially own more than 4.99% of the Common ...
(Date:9/17/2014)... N.J. , Sept. 17, 2014 Aethlon ... therapeutic devices to address infectious disease, cancer and other ... (ESI), disclosed today that each company will be presenting ... On September 18 th , Sahil Shah ... "Exosomes: A Multiplexed Platform for Clinical Management." ...
(Date:9/17/2014)... , Sept. 17, 2014  MiMedx Group, Inc. ... processor and marketer of patent protected regenerative biomaterials ... today the publication of another peer-reviewed clinical study.    ... A Multi-center Randomized Controlled Clinical Trial Evaluating the ... Membrane Allografts and Multi-layer Compression Therapy vs. Multi-layer ...
Breaking Biology Technology:Partial Breast Irradiation With Interstitial Brachytherapy Appears Appropriate For Women Previously Considered Unsuitable 2Partial Breast Irradiation With Interstitial Brachytherapy Appears Appropriate For Women Previously Considered Unsuitable 3Partial Breast Irradiation With Interstitial Brachytherapy Appears Appropriate For Women Previously Considered Unsuitable 4Oncothyreon Announces Proposed Public Offerings 2Aethlon Medical and Exosome Sciences To Present at the Exosomes & SingleCell Analysis Summit 2Aethlon Medical and Exosome Sciences To Present at the Exosomes & SingleCell Analysis Summit 3MiMedx Multi-Center Randomized, Controlled VLU Clinical Study Published In Peer-Reviewed Journal 2MiMedx Multi-Center Randomized, Controlled VLU Clinical Study Published In Peer-Reviewed Journal 3MiMedx Multi-Center Randomized, Controlled VLU Clinical Study Published In Peer-Reviewed Journal 4
... ... ... ... March 12 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY ) today announced that it will restate its 2008 financial statements contained in its Annual Report on Form 10-K for the ...
... LAKE, N.J. , March 11 Eisai Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved a five-day dosing regimen ... , ... , , ... ...
... China , March 11 /PRNewswire-Asia-FirstCall/ -- Tianyin,Pharmaceutical Co., Inc. ... ("TCM") based in Chengdu, China , today,announced it will present ... held March 15-17, 2010 in Dana Point, California ... Tuesday, March 16, 2010, ...
Cached Biology Technology:Oncothyreon consults with Division of Corporation Finance about accounting for 2008 License Agreement 2Oncothyreon consults with Division of Corporation Finance about accounting for 2008 License Agreement 3Oncothyreon consults with Division of Corporation Finance about accounting for 2008 License Agreement 4Oncothyreon consults with Division of Corporation Finance about accounting for 2008 License Agreement 5Oncothyreon consults with Division of Corporation Finance about accounting for 2008 License Agreement 6Oncothyreon consults with Division of Corporation Finance about accounting for 2008 License Agreement 7Oncothyreon consults with Division of Corporation Finance about accounting for 2008 License Agreement 8Oncothyreon consults with Division of Corporation Finance about accounting for 2008 License Agreement 9Oncothyreon consults with Division of Corporation Finance about accounting for 2008 License Agreement 10FDA Approves Five-Day Dosing Regimen for Dacogen(R) (decitabine) for Injection, Offering a New Outpatient Dosing Option for Myelodysplastic Syndromes (MDS) 2FDA Approves Five-Day Dosing Regimen for Dacogen(R) (decitabine) for Injection, Offering a New Outpatient Dosing Option for Myelodysplastic Syndromes (MDS) 3FDA Approves Five-Day Dosing Regimen for Dacogen(R) (decitabine) for Injection, Offering a New Outpatient Dosing Option for Myelodysplastic Syndromes (MDS) 4FDA Approves Five-Day Dosing Regimen for Dacogen(R) (decitabine) for Injection, Offering a New Outpatient Dosing Option for Myelodysplastic Syndromes (MDS) 5FDA Approves Five-Day Dosing Regimen for Dacogen(R) (decitabine) for Injection, Offering a New Outpatient Dosing Option for Myelodysplastic Syndromes (MDS) 6FDA Approves Five-Day Dosing Regimen for Dacogen(R) (decitabine) for Injection, Offering a New Outpatient Dosing Option for Myelodysplastic Syndromes (MDS) 7FDA Approves Five-Day Dosing Regimen for Dacogen(R) (decitabine) for Injection, Offering a New Outpatient Dosing Option for Myelodysplastic Syndromes (MDS) 8Tianyin Pharmaceutical Co., Inc. to Present at the 22nd Annual ROTH Capital Partners OC Growth Stock Conference on March 16 2Tianyin Pharmaceutical Co., Inc. to Present at the 22nd Annual ROTH Capital Partners OC Growth Stock Conference on March 16 3Tianyin Pharmaceutical Co., Inc. to Present at the 22nd Annual ROTH Capital Partners OC Growth Stock Conference on March 16 4
...
TNM-FH Insect Medium 1 liter...
IHC Polymer Detection Kit (Rabbit DAB)150 slides...
Performance, mycoplasma, virus, and endotoxin tested. Collected from calves 14 days old or less...
Biology Products: